Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Plus500 posts solid H1 results amid ongoing strategic expansion

(Sharecast News) - Fintech business Plus500 posted a solid set of H1 results on Monday, with strategic expansion and product diversification helping it maintain momentum across its trading platform business. Revenues rose 4% year-on-year to $415.1m, while underlying earnings ticked up 1% to $185.1m. EBITDA margins dipped slightly from 46% to 45%, reflecting increased investment in growth initiatives.

Plus500 said active customer numbers grew 2% to 179,931, with average revenue per user up 2% to $2,307. Acquisition costs per customer fell 17% to $1,237, supporting profitability.

The FTSE 250-listed group also announced an additional $165m in shareholder returns, bringing total buybacks for FY25 to $200m. Plus500 has now repurchased roughly 38% of its shares since its inception.

Plus 500 also noted that operational highlights included new regulatory licences in Canada and the UAE, a clearing membership with ICE Clear US, and the conditional acquisition of Mehta Equities in India.

Chief executive David Zruia said: "In the first half of the year, the strength of Plus500's globally diversified multi-asset offering was again evidenced by our accelerated operational, financial and strategic results. We delivered great progress during H1 2025 in further diversifying our business and strengthening our operating model.

"We look to the second half of the year and beyond with confidence."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.